Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

This is a Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the
efficacy and safety of MEDI9929 administered subcutaneously to adult subjects with moderate
to severe Atopic Dermatitis. Subjects will be randomized in a 1:1 fashion and will be
stratified at screening. Approximately 100 subjects are planned to be randomized at
approximately 35 sites in 6 countries

Inclusion Criteria:

- AD meeting Hanifin and Rajka criteria

- Age 18-75 years inclusive at screening

- Atopic dermatitis that affects greater than/equal to 10% body surface area

- Moderate to severe AD

- Effective birth control in line with protocol details

Exclusion Criteria:

- Active dermatologic conditions which may confuse the diagnosis of Atopic Dermatitis

- Hepatitis B, C or HIV

- Pregnant or breastfeeding

- History of anaphylaxis following any biologic therapy

- History of clinically significant infections within 4 weeks prior to Visit 3

- Diagnosis of helminth parasitic infection within 6 months to screening

- History of Cancer except basal cell

- Receipt of any marketed or investigational biologic agent within 4 months to visit 3

- Any clinically relevant abnormal finding

- Major surgery within 8 weeks prior to Visit 1